Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study (International Journal of Clinical Oncology, (2022), 27, 12, (1828-1838), 10.1007/s10147-022-02232-7)

Shunichi Sugawara, Masashi Kondo, Toshihide Yokoyama, Toru Kumagai, Makoto Nishio, Koichi Goto, Kazuhiko Nakagawa, Takashi Seto, Nobuyuki Yamamoto, Kentarou Kudou, Takayuki Asato, Pingkuan Zhang, Yuichiro Ohe

研究成果: ジャーナルへの寄稿コメント/討論査読

抄録

In the original publication, under section: Secondary end points, the sentence starting with: “KM estimated...” should read as: KM estimated median DoR was not reached (95% CI 13.9–not reached) in patients who had confirmed responses. The original publication has been corrected.

本文言語英語
ページ(範囲)724-725
ページ数2
ジャーナルInternational Journal of Clinical Oncology
28
5
DOI
出版ステータス出版済み - 05-2023

All Science Journal Classification (ASJC) codes

  • 外科
  • 血液学
  • 腫瘍学

フィンガープリント

「Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study (International Journal of Clinical Oncology, (2022), 27, 12, (1828-1838), 10.1007/s10147-022-02232-7)」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル